Ayers M, Pietanza MC, Piperdi B, Herbst RS. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
2 Kazutaka Hosoya1, Daichi Fujimoto, Takeshi Morimoto, et al. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-smallcell lung cancer patients: a retrospective multicenter study[J]. BMC Cancer, ...
为此,引入另一个 PD-L1 表达概念:联合阳性分数(Combined Positive Score,CPS)。 图:2022 版 CSCO 胃癌诊疗指南 CPS 应该是比 TPS 更加准确的 PD-L1 分层 biomarker,笔者推测可能帕博利珠单抗由于肺癌临床研究开展的比较早,为了继承和对比早期的临床研究,肺癌一直没有放弃 TPS 这个指标,帕博利珠单抗后续获批的宫颈癌...
2、CPS:综合阳性评分(Combined Positive Score) CPS=(PD-L1膜染色阳性肿瘤细胞+ PD-L1 膜染色阳性肿瘤相关免疫细胞(淋巴细胞、巨噬细胞))/总肿瘤细胞数 x100 3、TC:肿瘤细胞阳性率 TC=(任何强度PD-L1膜染色阳性肿瘤细胞数/总肿瘤细胞数)x100% 4、IC:肿瘤相关免疫细胞阳性率 IC=(任何强度PD-L1膜染色阳性的...
Gonzalez-Carmona MA. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol. 2022 Jul 25;12:933943. doi: 10.3389/fonc.2022.933943. PMID: 35957899; PMCID: PMC...
53 Haratake N, Toyokawa G, Tagawa T, et al. Positive conversion of PD-L1 expression af ter treatments with chemotherapy and nivolumab. Anticancer Res, 2017, 37(10): 5713-5717. doi: 10.21873/ anticanres.12009 54 Shin...
7 Cho, B.C, Lopes, G, Kowalski, D.M, et al. Relationship Between STK11 and KEAP1 Mutational Status and Efficacy in KEYNOTE-042: Pembrolizumab Monotherapy Versus Platinum-Based Chemotherapy as First-Line Therapy for PD-L1-Positive Advanced NSCLC[J]. https://doi.org/10.1158/1538-7445.am20...
相关研究表明评估免疫细胞的PD-L1 表达水平与免疫治疗药物响应度非常相关,CPS对临床帕博利珠单抗用药具有重要指导意义。因此,联合阳性分数(CombinedPositive Score,CPS)比TPS 更加准确评价PD-L1,现在大部分肿瘤诊疗指南更加推荐的是 CPS,CSCO肿瘤诊...
[20]MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-l1-positive advanced gastric cancer (keynote012): a multicentre, open-label, phase 1b trial[J]. The Lancet Oncology, 2016, 17(6): 717-726. DOI: 10.1016/s1470-2045(16)00175-3. ...
定义:任何强度 PD-L1 膜染色肿瘤细胞占肿瘤细胞的百分比。 计算方法: CPS 英文:Combined Positive Score 中文:联合阳性分数 定义:每 100 个肿瘤细胞中 PD-L1 染色的肿瘤细胞和肿瘤相关的免疫数之和。 计算方法: IPS 英文:Immune cell Proportion Score